In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
A new era in CNS drug delivery: Crossing the blood brain barrier
Advances in neuroscience are reshaping our understanding of the brain and opening new frontiers in how we diagnose, treat, and ultimately prevent neurological...